{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:51:23Z","timestamp":1761540683029},"reference-count":60,"publisher":"Wiley","issue":"s3","license":[{"start":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T00:00:00Z","timestamp":1146096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> The reduced mortality, improved joint outcomes and enhanced quality of life, which have been witnessed in the developed world for patients with haemophilia, have been an outstanding achievement. Advancements in biotechnology contributed significantly through the development of improved pathogen screening, viral inactivation techniques and the development of recombinant clotting factors. These were partnered with enhanced delivery of care through comprehensive haemophilia centres, adoption of home therapy and most recently effective prophylaxis. This came at great costs to governments, medical insurers and patients\u2019 families. In addition, barriers persist limiting the adoption and adherence of effective prophylactic therapy. Biotechnology has been successful at overcoming similar barriers in other disease states. Long\u2010acting biological therapeutics are an incremental advance towards overcoming some of these barriers. Strategies that have been successful for other therapeutic proteins are now being applied to factor VIII (FVIII) and include modifications such as the addition of polyethylene glycol (PEG) polymers and polysialic acids and alternative formulation with PEG\u2010modified liposomes. In addition, insight into FVIII structure and function has allowed targeted modifications of the protein to increase the duration of its cofactor activity and reduce its clearance <jats:italic>in vivo<\/jats:italic>. The potential advantages and disadvantages of these approaches will be discussed.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2006.01260.x","type":"journal-article","created":{"date-parts":[[2006,4,28]],"date-time":"2006-04-28T08:36:36Z","timestamp":1146213396000},"page":"42-51","source":"Crossref","is-referenced-by-count":40,"title":["Strategies towards a longer acting factor VIII"],"prefix":"10.1111","volume":"12","author":[{"given":"E. L.","family":"SAENKO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. W.","family":"PIPE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,4,27]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.01010.x"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00987.x"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1355-0691.2004.00881.x"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00981.x"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2001.00534.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00998.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.9.3S.32886"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)40291-2"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)40292-4"},{"key":"e_1_2_8_11_2","first-page":"249","article-title":"The uses and properties of PEG\u2010linked proteins","volume":"9","author":"Delgado C","year":"1992","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.12.2201"},{"key":"e_1_2_8_13_2","first-page":"1264","article-title":"Characterization of polyethylene glycol\u2010modified l\u2010asparaginase from Escherichia coli and its application to therapy of leukemia","volume":"77","author":"Yoshimoto T","year":"1986","journal-title":"Jpn J Cancer Res"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03575-0"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/bc000082g"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108788"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1050-1738(01)00124-4"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V59.3.594.594"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4838(86)90208-6"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1994.tb18839.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00350a035"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.11.6027"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)42201-6"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/bc990137i"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0142-9612(00)00193-9"},{"key":"e_1_2_8_26_2","first-page":"8","article-title":"Structural and functional role of the factor VIII B domain","volume":"89","author":"Pipe SW","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3591"},{"key":"e_1_2_8_28_2","volume-title":"Baxter announces collaborations to develop longer acting forms of blood clotting factors","author":"Baxter International, Inc"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(03)00108-X"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2005.06.007"},{"key":"e_1_2_8_31_2","first-page":"1","article-title":"Liposomal drug delivery systems \u2013 clinical applications","volume":"55","author":"Goyal P","year":"2005","journal-title":"Acta Pharm"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-100103136"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199408000-00005"},{"key":"e_1_2_8_34_2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1160\/TH04-08-0485","article-title":"Factor VIII efficient and specific non\u2010covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy","volume":"93","author":"Baru M","year":"2005","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_35_2","volume-title":"Bayer completes investigational new drug filing with FDA for longer\u2010acting Kogenate\u00ae product","author":"Bayer HealthCare"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4838(97)00056-3"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(01)00603-2"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-4165(03)00116-8"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01367.x"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.22.11851"},{"issue":"10","key":"e_1_2_8_41_2","first-page":"453a","article-title":"The conformation of the factor VIII light chain can modulate von Willebrand factor binding affinity without affecting cofactor activity in vitro and in vivo","volume":"94","author":"Pipe SW","year":"1999","journal-title":"Blood"},{"key":"e_1_2_8_42_2","first-page":"488a","article-title":"Inactivation\u2010resistant human coagulation factor VIIIa (IR8) corrects canine hemophilia A coagulopathy","volume":"82","author":"Nichols TC","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_43_2","first-page":"88a","article-title":"Inactivation\u2010resistant factor VIII provides superior hemostasis to wild\u2010type factor VIII in a murine hemophilia A model without increased thrombogenicity","volume":"102","author":"Thornburg CD","year":"2003","journal-title":"Blood"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.7.2413"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1110\/ps.0210002"},{"issue":"1","key":"e_1_2_8_46_2","first-page":"OC094","article-title":"A novel engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa","volume":"1","author":"Gale AJ","year":"2003","journal-title":"J Thromb Haemost"},{"key":"e_1_2_8_47_2","doi-asserted-by":"crossref","first-page":"2976a","DOI":"10.1182\/blood.V104.11.2976.2976","article-title":"Whole blood thromboelastogram assays demonstrate prolonged factor VIIIa potency for recombinant disulfide bond\u2010stabilized factor VIII variants","volume":"104","author":"Radtke K\u2010P","year":"2004","journal-title":"Blood"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.53.37685"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.34.23734"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.5.1703.005k20_1703_1708"},{"key":"e_1_2_8_51_2","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood.V95.11.3637","article-title":"In vivo inhibition of low density lipoprotein receptor\u2010related protein improves survival of factor VIII in the absence of von Willebrand factor","volume":"95","author":"Turecek PL","year":"2000","journal-title":"Blood"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2081"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4230"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1050-1738(00)00036-0"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M008046200"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M212053200"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.4.1935"},{"key":"e_1_2_8_58_2","doi-asserted-by":"crossref","first-page":"27137","DOI":"10.1016\/S0021-9258(19)61490-0","article-title":"Sites in the A2 subunit involved in the interfactor VIIIa interaction","volume":"275","author":"Koszelak ME","year":"2000","journal-title":"J Biol Chem"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1215"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi0520380"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.9.s1.12.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2006.01260.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2006.01260.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T04:20:55Z","timestamp":1695702055000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2006.01260.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,27]]},"references-count":60,"journal-issue":{"issue":"s3","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1111\/j.1365-2516.2006.01260.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2006.01260.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,27]]}}}